| Literature DB >> 21475239 |
S Claiborne Johnston1, Stephen L Hauser, Susan Desmond-Hellmann.
Abstract
Concerns about conflicts of interest have driven a wedge between academia and the pharmaceutical and devices industries. Although elevated concern for bias is justified, particularly when academics may affect drug sales, partnerships between industry and academia are essential to achieve the full promise of health improvement from the public investment in biomedical research. New models for such partnerships are developing and should be encouraged.Mesh:
Year: 2011 PMID: 21475239 DOI: 10.1038/nm0411-434
Source DB: PubMed Journal: Nat Med ISSN: 1078-8956 Impact factor: 53.440